Combination delaprilmanidipine as antihypertensive therapy in high-risk patients

Roberto Fogari, Amedeo Mugellini, Maria Circelli, Giovanni Cremonesi

Research output: Contribution to journalArticlepeer-review


The majority of patients with hypertension, and in particular high-risk patients or those with diabetes mellitus or renal dysfunction, are likely to require combination therapy with at least two antihypertensive agents (from different classes) to achieve their blood pressure (BP) target. The delaprilmanidipine fixed-dose combination consists of two antihypertensive agents with different, yet complementary, mechanisms of action. Delaprilmanidipine has demonstrated short- and long-term antihypertensive efficacy in a number of clinical studies in patients with hypertension with an inadequate response to monotherapy.Comparative studies have demonstrated that delaprilmanidipine is as effective as enalaprilhydrochlorothiazide (HCTZ) in patients with hypertension with an inadequate response to monotherapy, and as effective as irbesartanHCTZ, losartanHCTZ, olmesartan medoxomilHCTZ, ramiprilHCTZ and valsartanHCTZ in reducing BP in patients with hypertension and diabetes, or in obese patients with hypertension.Therapy with delaprilmanidipine also appears to exert beneficial effects that extend beyond a reduction in BP, including nephroprotective activity and an improvement in fibrinolytic balance, supporting its value as a treatment option in these patient populations at high or very high cardiovascular risk because of the presence of organ damage, diabetes or renal disease.

Original languageEnglish
Pages (from-to)439-453
Number of pages15
JournalClinical Drug Investigation
Issue number7
Publication statusPublished - 2011


  • ACE-inhibitors, therapeutic use
  • Calcium-channel-antagonists, therapeutic use
  • Delapril, therapeutic use
  • Delaprilmanidipine, therapeutic use
  • Hypertension, treatment
  • Manidipine, therapeutic use
  • Research-and-development.

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Combination delaprilmanidipine as antihypertensive therapy in high-risk patients'. Together they form a unique fingerprint.

Cite this